Glucocorticoid-Induced TNF Receptor–Related Protein Agonist Alone or With Nivolumab for Advanced Solid Tumors
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor-Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors: A Phase 1/2a Dose-Escalation and Cohort-Expansion Clinical Trial
JAMA Oncol 2019 Nov 07;[EPub Ahead of Print], KM Heinhuis, M Carlino, M Joerger, M Di Nicola, T Meniawy, S Rottey, V Moreno, A Gazzah, JP Delord, L Paz-Ares, C Britschgi, RJ Schilder, K O'Byrne, G Curigliano, E Romano, P Patah, R Wang, Y Liu, G Bajaj, LL SiuFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.